Organigram Global Inc(OGI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 2.08 | EPS (ttm) | 0.45 | Insider Own | 31.18% | Shs Outstand | 141.0M | Perf Week | 0.23% |
| Market Cap | 0.13B | Forward P/E | 21.23 | EPS next Y | -92.32% | Insider Trans | - | Shs Float | 97.0M | Perf Month | -13.44% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | 0.01 | Inst Own | 6.4% | Short Float | 4.96% | Perf Quarter | 0.99% |
| Income | 0.06B | P/S | 0.59 | EPS this Y | 525.61% | Inst Trans | -0.19% | Short Ratio | 5.63 | Perf Half Y | -32.91% |
| Sales | 0.22B | P/B | 0.39 | EPS next 5Y | - | ROA | 12.56% | Short Interest | 4.82M | Perf YTD | -44.1% |
| Book/sh | 2.43 | P/C | 16.11 | EPS past 3/5Y | 1.56% 43.19% | ROE | 19.95% | 52W High | -58.07% ($2.24) | Perf Year | -45.08% |
| Cash/sh | 0.06 | P/FCF | - | Sales past 3/5Y | 17.38% 23.51% | ROIC | 17.27% | 52W Low | 10.09% ($0.85) | Perf 3Y | -6.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 3137.32% | Gross Margin | 4.11% | Volatility(W/M) | 3.12% 3.91% | Perf 5Y | -89.52% |
| Dividend TTM | - | EV/Sales | 0.65 | Sales Y/Y TTM | 39.67% | Oper. Margin | -30.1% | ATR (14) | 0.04 | Perf 10Y | -88.43% |
| Dividend Ex-Date | - | Quick Ratio | 1.07 | EPS Q/Q | 1747.2% | Profit Margin | 27.86% | RSI (14) | 39.95 | Recom | 1.4 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.61 | Sales Q/Q | 49.47% | SMA20 | -0.54% ($0.95) | Beta | 1.55 | Target Price | $2.09 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/11 | SMA50 | -11.82% ($1.07) | Rel Volume | 0.2 | Prev Close | $0.94 |
| Employees | 1139 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 7080.56% 8.84% | SMA200 | -22.47% ($1.21) | Avg Volume(3M) | 0.86M | Price | $0.94 |
| IPO | 2014/8/27 | Option/Short | Yes/Yes | Trades | 392 | Volume | 168,397 | Change | 0.02% |
🌿 Organigram Global is a Canada-based cannabis cultivation and sales company. It supplies dried flower, pre-rolls, vapes, concentrates, oils, and edibles to both the recreational and medical markets, generating revenue through provincial cannabis board contracts, direct sales to medical patients, and international partnerships.
Over the past 1 year, on the lower side
58% below its 1-year high.
Traded less than usual. That is 20% of its average volume.
OGI has a sound balance sheet but weak earning power
Of every $100 in sales, $30.10 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +525.6% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,123. Peers typically go for $1,485.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -89.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 6.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #55 of 83 in the industry
Based on market cap of $132M.
DERM#53 Journey Medical Corp $140M PER - 
CRDL#54 Cardiol Therapeutics Inc $138M PER - OGI#55 Organigram Global Inc $132M PER 2.1 
BGM#56 BGM Group Ltd $120M PER - 
ORGO#57 Organogenesis Holdings Inc $116M PER - 
FAQ
What kind of company is OGI?
OGI belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of OGI?
The market cap of OGI is approximately $132M, ranking 4,315 within its sector.
What is the P/E ratio of OGI?
OGI has a P/E ratio of approximately 2.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OGI?
OGI has recorded a 52-week high of $2.24 and a low of $0.85.
